Peer-influenced content. Sources you trust. No registration required. This is HCN.

ReachMDInsomnia Treatment Goals: Restful Nights and Productive Days (CME)

Sleep Architecture and Neurotransmitters of Sleep

This Continuing Medical Education (CME) program offers a thorough exploration of sleep architecture and neurotransmitters, focusing on the pathophysiology and diagnosis of insomnia, and the role of the orexin system in the sleep/wake cycle.

Program Details

  • Overview: This CME program delves into the pathophysiology and diagnosis of insomnia, with a special focus on the role of the orexin system in the sleep/wake cycle.
  • Target Audience: Healthcare professionals aiming to enhance their understanding of sleep disorders and improve patient outcomes.
  • Learning Objectives: The program aims to provide a comprehensive understanding of insomnia’s impact on individuals’ quality of life, and to evaluate the latest treatments, including dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant.
  • Accreditation & Credit Designation Statements: This activity is jointly provided by Global Learning Collaborative (GLC) and TotalCME, LLC. The program offers 0.75 credits.

Transcript Summary

  • Dr. Mike Yurcheshen from the University of Rochester presents an insightful talk on sleep architecture and neurotransmitters. He discusses the changes in sleep patterns across the lifespan, highlighting the increase in sleep disruptions and decrease in slow-wave sleep as we age. He further delves into the role of various neurotransmitters during wakefulness and non-REM sleep, including glutamine, monoamines, acetylcholine, histamine, GABA, and adenosine. The talk concludes with a focus on orexin, a neurotransmitter regulating REM sleep, which has significant implications for individuals with type 1 narcolepsy and insomnia.

According to a study by the American Academy of Sleep Medicine, about 30% of adults have symptoms of insomnia.

More on Insomnia

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form